China's National Medical Products Administration approved Eli Lilly's once-daily oral obesity drug on November 12, 2026, making it the first oral non-peptide GLP-1 receptor agonist cleared for obesity in that market. The drug is branded Muyouda in China and Foundayo in the United States, where it is already approved alongside the United Kingdom and the United Arab Emirates.

The active molecule is orforglipron, a small molecule rather than a peptide. GLP-1 itself is a 30-amino-acid peptide that the digestive system breaks down, which is why the class has historically meant injections.

Why the chemistry matters

Novo Nordisk's oral semaglutide gets around that problem with an absorption enhancer called SNAC, and the protocol is demanding: an overnight fast, no more than 120 mL of water, and a 30-minute wait before eating, with roughly 1% of the peptide reaching the bloodstream. Orforglipron does none of that, binding inside the receptor's transmembrane helices rather than the extracellular peptide-binding domain, and patients can take it with or without food at any time.

The manufacturing side is the part fewer people discuss. A small molecule can be made in standard stainless-steel reactors like metformin or ibuprofen, with no cold chain, which is what Lilly's $3 billion China investment and its $200 million partnership with Pharmaron are aimed at.

Key results

The ATTAIN-1 Phase 3 trial enrolled 3,127 adults with obesity or overweight without diabetes and reported average weight loss of 12.4% on the 36mg daily dose over 72 weeks, against 0.9% on placebo. Results were published in the New England Journal of Medicine, with nearly 60% of participants on that dose losing at least 10% of body weight.

That 12.4% figure trailed Wegovy's roughly 15% average and knocked Lilly's shares when it landed in August 2025. The reporting argues the comparison underweighted what the pill removes: no needle, no cold storage, no fasting window.

Side effects and dropout

The common adverse events were the familiar gastrointestinal ones: nausea, vomiting and diarrhea. Discontinuation due to adverse events ran at about 10.3% at the highest dose, broadly consistent with the rest of the class.

The race with Novo

China had 532 million adults classified as overweight or obese by 2024, or 50.7%, per the China Development Research Foundation's 2026 report. Novo's oral semaglutide application has been accepted by the NMPA, so Lilly's lead in the oral lane is a head start rather than a moat.